Login / Signup

A novel nanotechnological mucoadhesive and fast-dissolving film for vaginal delivery of clotrimazole: design, characterization, and in vitro antifungal action.

Verônica Ferrari CerviCamila Parcianello SaccolTiciane da Rosa PinheiroRoberto Christ Vianna SantosMarcel Henrique Marcondes SariLetícia Cruz
Published in: Drug delivery and translational research (2022)
Pullulan (PUL) films containing pomegranate seed oil and Eudragit ® RS100 nanocapsules loaded with clotrimazole (CTZ-NC-PUL) were developed to treat vulvovaginal candidiasis (VVC). Our findings showed that the nanocapsule average diameter was around 163 ± 4 nm, with polydispersity index values of up to 0.1 ± 0.01 and positively charged zeta potential (+ 43.5 ± 0.7 mV). The pH was in the acid range (5.14 ± 0.12) and encapsulation efficiency was around 99.6%; CTZ nanoencapsulation promoted higher homogeneity values for the film (91%), and the stability studies displayed no changes in the drug content after 120 days for the CTZ-NC-PUL under refrigerated conditions. All formulations were considered non-irritant, and CTZ-NC-PUL promoted a controlled release of the drug (60% in 24 h) compared to CTZ-PUL (100% in 8 h). The permeation results corroborate the drug release, where higher CTZ amounts were found in the mucosa and receptor medium for CTZ-PUL (21.02 and 4.46 μg/cm 2 ). The films were fast dissolving (10 min), and CTZ-NC-PUL presented higher mucoadhesive properties; the antifungal activity against Candida albicans was maintained, and the in vitro efficacy of the film was proved. In conclusion, CTZ-NC-PUL formulation was considered promising and suitable for vaginal application against candida-related infections.
Keyphrases
  • candida albicans
  • room temperature
  • drug delivery
  • biofilm formation
  • drug release
  • reduced graphene oxide
  • escherichia coli
  • risk assessment
  • adverse drug
  • drug induced
  • carbon nanotubes
  • electronic health record